Zolasol 4 mg Powder for concentrate for solution for infusion
PDF Leaflet Revision Date: 31 May 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of metastatic ovarian carcinoma and small cell lung carcinoma.
Dosage (summary)
1.5 mg/mu00b2 IV daily for 5 days, repeat every 3 weeks; adjust for neutropenia.
Onset of Action / Duration
Onset: 8-11.7 weeks for ovarian cancer; 6.1 weeks for small cell lung cancer.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; may cause fetal harm.
Key Drug Interactions
- Increased myelosuppression with other cytotoxic agents.
Contraindications
- Severe hypersensitivity to topotecan
- Severe bone marrow depression
- Pregnancy
- Breastfeeding
Common side effects
- Neutropenia
- Thrombocytopenia
- Nausea
- Vomiting
- Diarrhea
Counselling Points
- Use effective contraception during and after treatment.
- Report signs of infection or bleeding.
- Avoid pregnancy during treatment.
Serious warnings
- Severe myelosuppression
- Risk of interstitial lung disease
- Monitor for neutropenic colitis
Important Disclaimer
The Zolasol 4 mg Powder for concentrate for solution for infusion professional information leaflet below is the property of Ando Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
